Oral Tablet Immunotherapy for Allergic Rhinitis: Advancing Management in the Pediatric Setting – American Academy of Pediatrics: New Jersey - Pretest (ID: i857-6) September 26, 2023

Please answer the following questions. Upon submission, you will be redirected to the meeting. To view CME information, click here.
1.Contact information:(Required.)
2.Which of the following best describes your profession?(Required.)
3.Which of the following best describes your specialty?(Required.)
4.How confident are you in the management of patients with AR/C in your practice?(Required.)
5.Uncontrolled AR/C increases the risk for development of which of the following:(Required.)
6.Jeremy is a 9-year-old boy with a history of repetitive sneezing, nasal itching, runny nose, watering eyes, and itching skin each spring. Results of his specific IgE tests are positive to Timothy grass, ragweed, and house dust mites. Which of the following allergens is the cause of his symptoms?(Required.)
7.According to the Pediatric Allergies in America Survey, which of the following is a persistent unmet need in the care of children with AR/C?(Required.)
8.According to current recommendations, allergen immunotherapy should be considered for patients with which of the following?(Required.)
9.Amanda is a 13-year-old girl with a 5-year history of moderate-to-severe AR/C symptoms year-round despite OTC pharmacotherapy with antihistamines and decongestants. Her parents express concern over the sheer amount of medication that she has been taking over the years and would like to reduce her medication exposure. Specific IgE testing indicates sensitization to ragweed and house dust mites. Which of the following would you prescribe?(Required.)
10.Which of the following describes FDA-approval status of oral sublingual immunotherapies?(Required.)